Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers.
Publication Title
Cancer Discov
Document Type
Article
Publication Date
8-1-2019
Abstract
Immunotherapies can mediate regression of human tumors with high mutation rates, but responses are rarely observed in patients with common epithelial cancers. This raises the question of whether patients with these common cancers harbor T lymphocytes that recognize mutant proteins expressed by autologous tumors that may represent ideal targets for immunotherapy. Using high-throughput immunologic screening of mutant gene products identified via whole-exome sequencing, we identified neoantigen-reactive tumor-infiltrating lymphocytes (TIL) from 62 of 75 (83%) patients with common gastrointestinal cancers. In total, 124 neoantigen-reactive TIL populations were identified, and all but one of the neoantigenic determinants were unique. The results of
Clinical Institute
Cancer
Clinical Institute
Digestive Health
Specialty/Research Institute
Earle A. Chiles Research Institute
Specialty/Research Institute
Oncology
Specialty/Research Institute
Gastroenterology
